Ipx-461

In individuals with ZSD, the PEX genes are mutated, leading to impaired peroxisome function and the accumulation of toxic compounds in the body. By activating PPARα, IPX-461 helps to bypass the defective peroxisomes and restore the breakdown of fatty acids and amino acids, thereby reducing the levels of toxic compounds in the body.

IPX-461 works by specifically targeting the HAO1 gene, which is involved in the production of the glycolate oxidase 1 enzyme. By reducing HAO1 expression, IPX-461 decreases the conversion of glycolate to glyoxylate, a precursor to oxalate. This results in lower oxalate levels, which can slow disease progression in PH1 and FSGS. IPX-461

IPX-461, also known as rivoglitazone, is a thiazolidinedione (TZD) derivative that was initially developed by a Japanese pharmaceutical company, Kissei Pharmaceutical Co., Ltd. (now part of Eisai Co., Ltd.), in the early 2000s. The compound was designed to target specific receptors involved in glucose and lipid metabolism, with the goal of treating type 2 diabetes mellitus and potentially other metabolic disorders. In individuals with ZSD, the PEX genes are

Type 2 diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels, insulin resistance, and impaired insulin secretion. The prevalence of type 2 diabetes is increasing globally, and there is a growing need for effective and safe therapeutic agents to manage the disease. IPX-461, a thiazolidinedione (TZD) derivative, was developed as a potential treatment for type 2 diabetes. (now part of Eisai Co

Several clinical trials were conducted to evaluate the efficacy and safety of IPX-461 in patients with type 2 diabetes:

The IPX-461 is a medication that has shown significant promise in the treatment of hyponatremia and other conditions. Future research should focus on: